Corticosteroid and long-acting beta2-adrenergic receptor agonist combination
This page covers all Corticosteroid and long-acting beta2-adrenergic receptor agonist combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Beta2-adrenergic receptor.
Targets
Phase 3 pipeline (4)
- Symbicort Turbohaler · Pearl Therapeutics, Inc. · Respiratory
Symbicort Turbohaler is a combination of budesonide and formoterol, a corticosteroid and a long-acting beta2-adrenergic receptor agonist, respectively, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD). - budesonide plus formoterol combination · Chiesi Farmaceutici S.p.A. · Respiratory
Budesonide is a corticosteroid that reduces inflammation, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes airway muscles. - Seretide Evohaler · FLUIDDA nv · Respiratory
Seretide Evohaler is a combination of fluticasone and salmeterol, which work together to reduce inflammation and bronchospasm in the airways. - Symbicort TBH - Turbuhaler · AstraZeneca · Respiratory
Symbicort TBH is a combination of budesonide and formoterol, a corticosteroid and a long-acting beta2-adrenergic receptor agonist, respectively, used to control symptoms of asthma and COPD.
Patent intelligence
- corticosteroid and long acting beta2 adrenergic receptor agonist combination patent landscape — aggregated cliff calendar, attackable patents, originator estates